Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02111551 · ClinicalTrials.gov registry record · Phase 1
Phase I Nicotinic Agonist Treatment Trial for Autism
A Phase 1 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02111551 is a Phase 1 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 2 participants.
The verdict
NCT02111551, a Phase 1 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study plans to learn more about whether a nicotine-like investigational new drug, DMXB-A \[3-(2,4-dimethoxybenzylidene) anabaseine\] may have positive effects on mental focus and may help us to find new types of treatment for autism spectrum disorder. Subjects will come in for a screening visit and three more drug visits. There will be at least one week between each drug visit to allow the drug to be eliminated from your system completely. During each drug visit subjects will receive either a placebo (a capsule that looks like medicine but is not real), 75 mg of DMXB-A, or 150 mg of DMXB-A. During the drug day vital signs and well being will be monitored by the study physician. Subjects will complete some paper and pencil tasks to test memory, attention, speed, and problem solving, some rating scales and questionnaires, and the study team will record brain wave patterns with an electroencephalogram (EEG) .
Interventions
- OTHER placebo
- DRUG DMXB-A 150 mg
- DRUG DMXB-A 75 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02111551
The ClinicalTrials.gov registry entry for NCT02111551 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02111551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02111551 about?
NCT02111551 is a clinical study titled "Phase I Nicotinic Agonist Treatment Trial for Autism". This study plans to learn more about whether a nicotine-like investigational new drug, DMXB-A \[3-(2,4-dimethoxybenzylidene) anabaseine\] may have positive effects on mental focus and may help us to find new types of treatment for autism spectrum disorder. Subjects will come in for a screening visit...
What is the current status of trial NCT02111551?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2015-06. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02111551?
The interventions under investigation include: placebo (OTHER), DMXB-A 150 mg (DRUG), DMXB-A 75 mg (DRUG).
Who is sponsoring clinical trial NCT02111551?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.